Membrane associated proteases and their inhibitors in tumour angiogenesis

Journal of Clinical Pathology

Volumn 57, Issue 6, 2004, Pages 577-584

  Noel, A ^a   Maillard, C ^a   Rocks, N ^a   Jost, M ^a   Chabottaux, V ^a   Sounni, N E ^a   Maquoi, E ^a   Cataldo, D ^a   Foidart, J M ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DISINTEGRIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITOR; MEMBRANE PROTEIN; METALLOPROTEINASE; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE; PROTEINASE INHIBITOR; SERINE PROTEINASE; SUBSTANCE P; TISSUE INHIBITOR OF METALLOPROTEINASE;

CANCER SURVIVAL; CELL FUNCTION; CELL SURFACE; CONCENTRATION (PARAMETERS); CORRELATION ANALYSIS; ENZYME ACTIVITY; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; REVIEW; TUMOR GROWTH; TUMOR VASCULARIZATION;

CELL MEMBRANE; ENDOPEPTIDASES; HUMANS; MATRIX METALLOPROTEINASES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEASE INHIBITORS; SERINE ENDOPEPTIDASES; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 2642516344     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2003.014472     Document Type: Review

References (136)

1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
2. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 2001;21:1104-17.
3. Puente XS, Sanchez LM, Overall CM, et al. Human and mouse proteases: a comparative genomic approach. Nat Rev Genet 2003;4:544-58.
4. Rifkin DB, Mazzieri R, Munger JS, et al. Proteolytic control of growth factor availability. APMIS 1999;107:80-5.
5. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
6. McQuibban GA, Gong JH, Wong JP, et al. Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood 2002;100:1160-7.
7. Luttun A, Carmeliet P. Genetic studies on the role of proteinases and growth factors in atherosclerosis and aneurysm formation. Ann N Y Acad Sci 2001;947:124-32.
8. Collen D. The plasminogen (fibrinolytic) system. Thromb Haemost 1999;82:259-70.
9. Parfyonova YV, Plekhanova OS, Tkachuk VA. Plasminogen activators in vascular remodeling and angiogenesis. Biochemistry Mosc 2002;67:119-34.
10. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000;57:25-40.
11. Wind T, Hansen M, Jensen JK, et al. The molecular basis for anti-proteolytic and non-proteolytic functions of plasminogen activator inhibitor type-1 : roles of the reactive centre loop, the shutter region, the flexible joint region and the small serpin fragment. Biol Chem 2002;383:21-36.
12. Rakic JM, Maillard C, Jost M, et al. Role of plasminogen activator-plasmin system in tumor angiogenesis. Cell Mol Life Sci 2003;60:463-73.
13. Carmeliet P, Collen D. Transgenic mouse models in angiogenesis and cardiovascular disease. J Pathol 2000;190:387-405.
14. Blasi F. uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? Immunol Today 1997;18:415-17.
15. Bugga TH, Kombrinck KW, Flick MJ, et al. Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell 1996;87:709-19.
16. Chapman HA. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 1997;9:714-24.
17. Preissner KT, Kanse SM, May AE. Urokinase receptor: a molecular organizer in cellular communication. Curr Opin Cell Biol 2000;12:621-8.
18. Kjoller L. The urokinase plasminogen activator receptor in the regulation of the actin cytoskeleton and cell motility. Biol Chem 2002;383:5-19.
19. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002;3:932-43.
20. Blasi F. The urokinase receptor. A cell surface, regulated chemokine. APMIS 1999;107:96-101.
21. Blasi F. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system. Thromb Haemost 1999;82:298-304.
22. Busso N, Masur SK, Lazega D, et al. Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction. in human epithelial cells. J Cell Biol 1994;126:259-70.
23. Xue W, Mizukami I, Tod III RF, et al. Urokinase-type plasminogen activator receptors associate with β1 and β3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res 1997;57:1682-9.
24. Wei Y, Yang X, Liu Q, et al. A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J Cell Biol 1999;144:1285-94.
25. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463-516.
26. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 2002;3:207-14.
27. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002;2:657-72.
28. Zucker S, Pei D, Cao J, et al. Membrane type-matrix metalloproteinases (MT-MMP). Curr Top Dev Biol 2003;54:1-74.
29. Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002;21:2245-52.
30. Oh J, Takahashi R, Kondo S, et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001;107:789-800.
31. Weaver VM. Membrane-associated MMP regulators: novel cell adhesion tumor suppressor proteins? Dev Cell 2002;2:6-7.
32. Takino T, Sato H, Yamamoto E, et al. Cloning of a human gene potentially encoding a novel matrix metalloproteinase having a C-terminal transmembrane domain. Gene 1995;155:293-8.
33. Will H, Hinzmann B. cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane segment. Eur J Biochem 1995;231:602-8.
34. Llano E, Pendas AM, Freije JP, et al. Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase is overexpressed in brain tumors. Cancer Res 1999;59:2570-6.
35. Yana I, Seiki M. MT-MMPs play pivotal roles in cancer dissemination. Clin Exp Metastasis 2002;19:209-15.
36. Strongin AY, Collier I, Bannikov G, et al. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995;270:5331-8.
37. Zucker S, Drews M, Conner C, et al. Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP). J Biol Chem 1998;273:1216-22.
38. Overall CM, King AE, Bigg HF, et al. Identification of the TIMP-2 binding site on the gelatinase A hemopexin C-domain by site-directed mutagenesis and the yeast two-hybrid system. Ann N Y Acad Sci 1999;878:747-53.
39. Deryugina EI, Ratnikov B, Monosov E, et al. MT1-MMP initiates activation of pro-MMP-2 and integrin alphavbeta3 promotes maturation of MMP-2 in breast carcinoma cells. Exp Cell Res 2001;263:209-23.
40. Morrison CJ, Butler GS, Bigg HF, et al. Cellular activation of MMP-2 (gelatinase A) by MT2-MMP occurs via a TIMP-2-independent pathway. J Biol Chem 2001;276:47402-10.
41. Knauper V, Lopez-Otin C, Smith B, et al. Biochemical characterization of human collagenase-3. J Biol Chem 1996;271:1544-50.
42. d'Ortho MP, Will H, Atkinson S, et al. Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur J Biochem 1997;250:751-7.
43. Koshikawa N, Giannelli G, Cirulli V, et al. Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol 2000;148:615-24.
44. Hotary K, Allen E, Punturieri A, et al. Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3. J Cell Biol 2000;149:1309-23.
45. Hotary KB, Yana I, Sabeh F, et al. Matrix metalloproteinases (MMPs) regulate fibrin-invasive activity via MT1-MMP-dependent and -independent processes. J Exp Med 2002;195:295-308.
46. Giannelli G, Falk-Marzillier J, Schiraldi O, et al. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 1997;277:225-8.
47. Gilles C, Polette M, Coraux C, et al. Contribution of MT1-MMP and of human laminin-5 gamma2 chain degradation to mammary epithelial cell migration. J Cell Sci 2001;114:2967-76.
48. Kajita M, Itoh Y, Chiba T, et al. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol 2001;153:893-904.
49. Belkin AM, Akimov SS, Zaritskaya LS, et al. Matrix-dependent proteolysis of surface transglutaminase by membrane-type metalloproteinase regulates cancer cell adhesion and locomotion. J Biol Chem 2001;276:18415-22.
50. Wang X, Pei D. Shedding of membrane type matrix metalloproteinase 5 by a furin-type convertase: a potential mechanism for down-regulation. J Biol Chem 2001;276:35953-60.
51. Uekita T, Itoh Y, Yana I, et al. Cytoplasmic tail-dependent internalization of membrane-type 1 matrix metalloproteinase is important for its invasion-promoting activity. J Cell Biol 2001;155:1345-56.
52. Maquoi E, Peyrollier K, Noel A, et al. Regulation of membrane-type 1 matrix metalloproteinase activity by vacuolar H+-ATPases. Biochem J 2003;373:19-24.
53. Maquoi E, Frankenne F, Baramova E, et al. Membrane type 1 matrix metalloproteinase-associated degradation of tissue inhibitor of metalloproteinase 2 in human tumor cell lines [in process citation]. J Biol Chem 2000;275:11368-78.
54. Butler GS, Butler MJ, Atkinson SJ, et al. The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem 1998;273:871-80.
55. Killar L, White J, Black R, et al. Adamalysins. A family of metzincins including TNF-alpha converting enzyme (TACE). Ann N Y Acad Sci 1999;878:442-52.
56. Blobel CP. Functional and biochemical characterization of ADAMs and their predicted role in protein ectodomain shedding. Inflamm Res 2002;51:83-4.
57. Bogenrieder T, Herlyn M. Cell-surface proteolysis, growth factor activation and intercellular communication in the progression of melanoma. Crit Rev Oncol Hematol 2002;44:1-15.
58. Becherer JD, Blobel CP. Biochemical properties and functions of membrane-anchored metalloprotease-disintegrin proteins (ADAMs). Curr Top Dev Biol 2003;54:101-23.
59. Black RA, White JM. ADAMs: focus on the protease domain. Curr Opin Cell Biol 1998;10:654-659.
60. Kheradmand F, Werb Z. Shedding light on sheddases: role in growth and development. Bioessays 2002;24:8-12.
61. Black RA. Tumor necrosis factor-alpha converting enzyme. Int J Biochem Cell Biol 2002;34:1-5.
62. Iba K, Albrechtsen R, Gilpin BJ, et al. Cysteine-rich domain of human ADAM 12 (meltrin alpha) supports tumor cell adhesion. Am J Pathol 1999;154:1489-501.
63. McQuibban GA, Gong JH, Tam EM, et al. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protern-3. Science 2000;289:1202-6.
64. Yoshimura T, Tomita T, Dixon MF, et al. ADAMs (a disintegrin and metalloproteinase) messenger RNA expression in Helicobacter pylori-infected, normal, and neoplastic gastric mucosa. J Infect Dis 2002;185:332-40.
65. Amour A, Knight CG, Webster A, et al. The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett 2000;473:275-9.
66. Zhang XP, Kamata T, Yokoyama K, et al. Specific interaction of the recombinant disintegrin-like domain of MDC-15 (metargidin, ADAM-15) with integrin alphavbeta3. J Biol Chem 1998;273:7345-50.
67. Netzel-Arnett S, Hooper JD, Szabo R, et al. Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev 2003;22:237-58.
68. Szabo R, Wu Q, Dickson RB, et al. Type II transmembrane serine proteases. Thromb Haemost 2003;90:185-93.
69. Hooper JD, Clements JA, Quigley JP, et al. Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes. J Biol Chem 2001;276:857-60.
70. Kim DR, Sharmin S, Inoue M, et al. Cloning and expression of novel mosaic serine proteases with and without a transmembrane domain from human lung. Biochim Biophys Acta 2001;1518:204-9.
71. Lang JC, Schuller DE. Differential expression of a novel serine protease homologue in squamous cell carcinoma of the head and neck. Br J Cancer 2001;84:237-43.
72. Velasco G, Cal S, Quesada V, et al. Matriptase-2, a membrane-bound mosaic serine proteinase predominantly expressed in human liver and showing degrading activity against extracellular matrix proteins. J Biol Chem 2002;277:37637-46.
73. Lee SL, Dickson RB, Lin CY. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 2000;275:36720-5.
74. Takeuchi T, Harris JL, Huang W, et al. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 2003;275:26333-42.
75. Oberst M, Anders J, Xie B, et al. Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am J Pathol 2001;158:1301-11.
76. Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-6.
77. Afar DE, Vivanco I, Hubert RS, et al. Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia. Cancer Res 2001;61:1686-92.
78. Wollropp C, Hahnel S, Muller-Pillasch F, et al. A novel transmembrane serine protease (TMPRSS3) overexpressed in pancreatic cancer. Cancer Res 2000;60:2602-6.
79. Benoud CM, Oberst M, Dickson RB, et al. Deregulated activation of matriptase in breast cancer cells. Clin Exp Metastasis 2002;19:639-49.
80. Bhott AS, Takeuchi T, Ylstra B, et al. Quantitation of membrane type serine protease 1 (MT-SP1) in transformed and normal cells. Biol Chem 2003;384:257-66.
81. Kong JY, Dolled-Filhart M, Ocal IT, et al. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 2003;63:1101-5.
82. Lin CY, Anders J, Johnson M, et al. Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J Biol Chem 1999;274:18237-42.
83. Takeuchi T, Shuman MA, Craik CS. Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci U S A 1999;96:11054-61.
84. Ihara S, Miyoshi E, Ko JH, et al. Prometastatic effect of N-acetylglucosaminyltransferase V is due to modification and stabilization of active matriptase by adding beta 1-GlcNAc branching. J Biol Chem 2003;277:16960-7.
85. Aimes RT, Zijlstra A, Hooper JD, et al. Endothelial cell serine proteases expressed during vascular morphogenesis and angiogenesis. Thromb Haemost 2003;89:561-72.
86. Schmitt M, Wilhelm O, Reuning U, et al. The urokinase plasminogen activator system as a novel target for tumour therapy. Fibrinolysis and Proteolysis 2000;14:114-32.
87. Mazar AP. The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer. Anticancer Drugs 2001;12:387-400.
88. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002;99:157-66.
89. Carmeliet P, Collen D. Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system. Thromb Res 1998;91:255-85.
90. Masson R, Lefebvre O, Noel A, et al. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J Cell Biol 1998;140:1535-41.
91. Zhou Z, Apte SS, Soininen R, et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci U S A 2000;97:4052-57.
92. Carmeliet P, Collen D. Gene manipulation and transfer of the plasminogen and coagulation system in mice. Sermin Thromb Hemost 1996;22:525-42.
93. Leco KJ, Waterhouse P, Sanchez OH, et al. Spontaneous air space enlargement in the lungs of mice lacking tissue inhibitor of metalloproteinases-3 (TIMP-3). J Clin Invest 2001;108:817-29.
94. Bajou K, Noel A, Gerard RD, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998;4:923-8.
95. Devy L, Blacher S, Grignet-Debrus C, et al. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J 2002;16:147-54.
96. Bajou K, Masson V, Gerard RD, et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin: implications for antiangiogenic strategies. J Cell Biol 2001;152:777-84.
97. Gutierrez LS, Schulman A, Brito-Robinson T, et al. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res 2000;60:5839-47.
98. Curino A, Mitola DJ, Aaronson H, et al. Plasminogen promotes sarcoma growth and suppresses the accumulation of tumor-infiltrating macrophages. Oncogene 2002;21:8830-42.
99. Bugge TH, Kombrinck KW, Xiao Q, et al. Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice. Blood 1997;90:4522-31.
100. Bugge TH, Lund LR, Kombrinck KK, et al. Reduced metastasis of polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene 1998;16:3097-104.
101. Sabapathy KT, Pepper MS, Kiefer F, et al. Polyoma middle T-induced vascular tumor formation: the role of the plasminogen activator/plasmin system. J Cell Biol 1997;137:953-63.
102. Montesono R, Pepper MS, Mohle-Steinlein U, et al. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell 1990;62:435-45.
103. Noel A, Bajou K, Masson V, et al. Regulation of cancer invasion and vascularization by plasminogen activator inhibitor-1. Fibrinolysis and Proteolysis 1999;13:220-5.
104. Eitzman DT, Krauss JC, Shen T, et al. Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma. Blood 1996;87:4718-22.
105. Almholt K, Nielsen BS, Frandsen TL, et al. Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice. Oncogene 2003;22:4389-97.
106. Stefansson S, Petitclerc E, Wong MK, et al. Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem 2001;276:8135-41.
107. Rakic JM, Lambert V, Munaut C, et al. Mice without uPA, tPA, or plasminogen genes are resistant to experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2003;44:1732-9.
108. Deng G, Curriden SA, Wang S, et al. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 1996;134:1-9.
109. Waltz DA, Natkin LR, Fujita RM, et al. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 1997;100:58-67.
110. Koyogoki N, Kawasaki A, Ebata T, et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995;182:1777-83.
111. Czekoy RP, Aertgeerts K, Curriden SA, et al. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 2003;160:781-91.
112. Holmbeck K, Bianco P, Caterina J, et al. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 1999;99:81-92.
113. Sounni NE, Baramova EN, Munaut C, et al. Expression of membrane type 1 matrix metalloproteinase (MT1-MMP) in A2058 melanoma cells is associated with MMP-2 activation and increased tumor growth and vascularization. Int J Cancer 2002;98:23-8.
114. Sounni NE, Devy L, Hajitou A, et al. MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. FASEB J 2002;16:555-64.
115. Belien AT, Paganetti PA, Schwab ME. Membrane-type 1 matrix metalloprotease (MT1-MMP) enables invasive migration of glioma cells in central nervous system white matter. J Cell Biol 1999;144:373-84.
116. Deryugina EI, Soroceanu L, Strongin AY. Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis. Cancer Res 2002;62:580-8.
117. Deryugina EI, Bourdon MA, Jungwirth K, et al. Functional activation of integrin alpha V beta 3 in tumor cells expressing membrane-type 1 matrix metalloproteinase. Int J Cancer 2000;86:15-23.
118. Hotary K, Allen E, Brooks PC, et al. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 2003;114:33-45.
119. Kahari VM, Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 1999;31:34-45.
120. Wang M, Liu YE, Greene J, et al. Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4. Oncogene 1997;14:2767-74.
121. Ahonen M, Boker AH, Kahari VM. Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptasis in melanoma cells. Cancer Res 1998;58:2310-15.
122. Noel A, Boulay A, Kebers F, et al. Demonstration in vivo that stromelysin-3 functions through its proteolytic activity. Oncogene 2000;19:1605-12.
123. Noel A, Hajitou A, L'Hoir C, et al. Inhibition of stromal matrix metalloproteases: effects on breast-tumor promotion by fibroblasts. Int J Cancer 1998;76:267-73.
124. Grignon DJ, Sakr W, Toth M, et al. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res 1996;56:1654-9.
125. Remacle A, McCarthy K, Noel A, et al. High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int J Cancer 2000;89:118-21.
126. Baker AH, George SJ, Zaltsman AB, et al. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer 1999;79:1347-55.
127. Guedez L, Courtemanch L, Stetler-Stevenson M. Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells. Blood 1998;92:1342-9.
128. Guedez L, McMarlin AJ, Kingma DW, et al. Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis. Am J Pathol 2001;158:1207-15.
129. Murphy AN, Unsworth EJ, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 1993;157:351-8.
130. Hajitau A, Sounni NE, Devy L, et al. Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis. Cancer Res 2001;61:3450-7.
131. Itoh Y, Takamura A, Ito N, et al. Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion. EMBO J 2001;20:4782-93.
132. Lehti K, Lohi J, Juntunen MM, et al. Oligomerization through hemopexin and cytoplasmic domains regulates the activity and turnover of membrane-type 1 matrix metalloproteinase. J Biol Chem 2002;277:8440-8.
133. Coussens IM, Fingleton B, Matrisian IM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387-92.
134. Lamfers ML, Grimbergen JM, Aalders MC, et al. Gene transfer of the urokinase-type plasminogen activator receptor-targeted matrix metalloproteinase inhibitor TIMP-1.ATF suppresses neointima formation more efficiently than tissue inhibitor of metalloproteinase-1. Circ Res 2002;91:945-52.
135. Dano K, Romer J, Nielsen BS, et al. Cancer invasion and tissue remodeling - cooperation of protease systems and cell types. APMIS 1999;107:120-7.
136. Lund LR, Romer J, Bugge TH, et al. Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO J 1999;18:4645-56.